发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
:We report the final results from a multicenter, open-label phase I study of carfilzomib plus lenalidomide and dexamethasone in Japanese patients with heavily pretreated relapsed and/or refractory multiple myeloma (RRMM). Twenty-six RRMM patients were enrolled and received a median of 4.0 prior regimens; 12/26 patients (46.2%) completed the planned 18 administration cycles (mean number of cycles: 14.5 ± 4.9). The safety profile was consistent with that of previous carfilzomib studies. All patients experienced adverse events (AEs), but no new safety concerns were observed. The most common grade ≥ 3 AEs (incidence: ≥ 10%) were lymphocyte count decreased (46.2%), platelet count decreased (42.3%), and neutrophil count decreased (34.6%). The overall response rate was 88.5% (23/26; 90% confidence interval: 72.8-96.8). Complete response (CR) or better was achieved by 30.8% of patients compared with 3.8% in the interim analysis. The median time to CR or better response was 9.4 months. Median progression-free survival and duration of response were 19.5 months and 20.3 months, respectively. Median overall survival was not reached. Long-term administration of carfilzomib produced deep response and long-term disease control. The combination of carfilzomib plus lenalidomide and dexamethasone was well tolerated and showed promising clinical efficacy for heavily pretreated RRMM patients. CLINICAL TRIAL REGISTRATION: This clinical trial was registered in the database clinicaltrials.jp (clinical trial registration number: Japic CTI 142677).
展开更多
最新影响因子:2.319 | 期刊ISSN:0925-5710 | CiteScore:1.59 |
出版周期:Monthly | 是否OA:YES | 出版年份:1991 |
期刊官方网址:http://www.springer.com/medicine/internal/journal/12185
自引率:6.40% | 研究方向:医学-血液学 |
出版地区:JAPAN |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
The International Journal of Hematology is the official journal of The Japanese Society of Hematology and is read by more than 6,000 hematologists, oncologists, and internists worldwide. A leading international journal, IJH has an impact factor of 1.212. The journal provides the opportunity for rapid and carefully reviewed publications in the fields of clinical and experimental hematology.
《国际血液学杂志》是日本血液学学会的官方期刊,全世界有6000多名血液学家、肿瘤学家和内科医生阅读。国际领先期刊IJH的影响因子为1.212。该杂志为临床和实验血液学领域的快速和仔细审查的出版物提供了机会。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
HEMATOLOGY (血液学) 4区 |
47/71 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
198 | 189 | 9 |
引文计数(2018)
文献(2015-2017)
1000次引用
629篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Hematology
|
#58/120
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
接受率: 中等(50%命中)
影响因子:2.566
ISSN:0739-7240
研究方向:农林科学-奶制品与动物科学
影响因子:6.497
ISSN:1172-7047
研究方向:医学-精神病学
影响因子:1.297
ISSN:0028-2804
研究方向:医学-精神病学
影响因子:4.604
ISSN:1092-8529
研究方向:医学-精神病学
影响因子:5.345
ISSN:1398-5647
研究方向:医学-精神病学
影响因子:3.492
ISSN:1540-2002
研究方向:CLINICAL NEUROLOGY-PSYCHIATRY
影响因子:4.562
ISSN:0269-8811
研究方向:医学-精神病学
影响因子:6.533
ISSN:0165-0327
研究方向:医学-精神病学
影响因子:5.415
ISSN:0924-977X
研究方向:医学-精神病学
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
INTERNATIONAL JOURNAL OF HEMATOLOGY 投稿经验
(由下方点评分析获得,1人参与,14947人阅读)